{"entity":{"id":"nct05724563","kind":"trial","name":"Domvanalimab and Zimberelimab in Advanced Liver Cancers","aka":[],"tldr":"A phase 2 trial of zimberelimab and domvanalimab in gallbladder cancer and other biliary tract cancers, run by University of Texas Southwestern Medical Center, active and no longer recruiting.","summary":"Domvanalimab and Zimberelimab in Advanced Liver Cancers is a phase 2 interventional study registered as NCT05724563 by University of Texas Southwestern Medical Center, with a registry enrolment figure of 58 participants, started 2023-06-12 and due to reach its primary completion in 2027-12-31. Interventions recorded: Zimberelimab, Domvanalimab. Conditions listed: Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma. Gallbladder cancer is named in the registry entry: \"1. Patient must have a histologically confirmed diagnosis consistent with HCC or bile duct cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gall bladder cancers); known fibrolamella\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05724563","url":"https://clinicaltrials.gov/study/NCT05724563"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["zimberelimab","domvanalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05724563-nat-commun-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05724563","phase":"2","setting":"Phase II Basket Trial of Domvanalimab (AB154) and Zimberelimab (AB122) in Advanced Hepatobiliary Cancers","sponsor":"University of Texas Southwestern Medical Center","enrolled":58,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05724563/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/"},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}],"paper":[{"id":"paper-nct05724563-nat-commun-2025","kind":"paper","name":"Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial","route":"/key-papers/paper-nct05724563-nat-commun-2025/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}